Low dosage kinetic hydrate inhibitors for natural gas production systems
Copolymers containing acryloylmorpholine and vinylimidazole, and optionally vinylcaprolactam and/or n-vinyl pyrrolidone, have shown superior results in hydrate inhibition tests at conditions of 7° C. subcooling dosed at 1 vol % based on the water cut of the system fluids. The copolymer product has also passed high TDS (total dissolved solids) brine compatibility tests and secondary property tests including foaming and hot injection tests which make it useful as a kinetic hydrate inhibitor in gas production systems susceptible to the formation of natural gas hydrates.
1. A method for inhibiting formation of hydrates consisting essentially of contacting a fluid including water and hydrate-forming guest molecules that form hydrates at hydrate forming conditions, with an amount of a kinetic hydrate inhibitor (KHI) effective for inhibiting hydrate formation at the hydrate forming conditions, where the KHI is selected from the group consisting of:
a copolymer comprising monomers selected from the group consisting of acryloylmorpholine, vinylimidazole, n-vinyl pyrrolidone and combinations thereof; and
a terpolymer selected from the group consisting of:
acryloylmorpholine, vinylimidazole, and vinylcaprolactam monomers,
vinylimidazole, vinylcaprolactam, and n-vinyl pyrrolidone monomers, and
acryloylmorpholine, vinylimidazole, and n-vinyl pyrrolidone monomers.
2. The method of claim 1 where:
in case the KHI is a copolymer it is a copolymer of acryloylmorpholine and vinylimidazole, and
in case the KHI is a terpolymer it is a terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam.
3. The method of claim 2 where:
in case of the copolymer of acryloylmorpholine and vinylimidazole, the molar ratio of acryloylmorpholine to vinylimidazole ranges from about 1:99 to about 99:1; and
in case of the terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam, the molar ratio of acryloylmorpholine to vinylimidazole to vinylcaprolactam ranges from about 1:1:98 to about 1:98:1 to about 98:1:1.
4. The method of claim 1 where the effective amount of the KHI in the fluid ranges from about 1 to about 15 vol % based on the water in the fluid.
5. The method of claim 1 where the fluid is present in a wellbore, a pipeline, an umbilical, a pipe, a transfer line, a valve, a slug catcher, and combinations thereof.
6. The method of claim 1 where the water is brine.
7. A method for inhibiting formation of hydrates consisting essentially of contacting a fluid including brine and hydrate-forming guest molecules that form hydrates at hydrate forming conditions, with from about 1 to about 15 vol % based on the water in the fluid of a kinetic hydrate inhibitor (KHI) effective for inhibiting hydrate formation at the hydrate forming conditions, where the KHI is selected from the group consisting of:
a copolymer comprising monomers selected from the group consisting of acryloylmorpholine, vinylimidazole, n-vinyl pyrrolidone and combinations thereof; and
a terpolymer selected from the group consisting of:
acryloylmorpholine, vinylimidazole, and vinylcaprolactam monomers,
vinylimidazole, vinylcaprolactam, and n-vinyl pyrrolidone monomers, and
acryloylmorpholine, vinylimidazole, and n-vinyl pyrrolidone monomers.
8. The method of claim 7 where:
in case the KHI is a copolymer it is a copolymer of acryloylmorpholine and vinylimidazole, and
in case the KHI is a terpolymer it is a terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam.
9. The method of claim 8 where:
in case of the copolymer of acryloylmorpholine and vinylimidazole, the molar ratio of acryloylmorpholine to vinylimidazole ranges from about 1:99 to about 99:1; and
in case of the terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam, the molar ratio of acryloylmorpholine to vinylimidazole to vinylcaprolactam ranges from about 1:1:98 to about 1:98:1 to about 98:1:1.
10. The method of claim 7 where the fluid is present in a wellbore, a pipeline, an umbilical, a pipe, a transfer line, a valve, a slug catcher, and combinations thereof.
11. A method for inhibiting formation of hydrates consisting of contacting a fluid including brine and hydrate-forming guest molecules that form hydrates at hydrate forming conditions, with from about 1 to about 15 vol % based on the water in the fluid of a kinetic hydrate inhibitor (KHI) effective for inhibiting hydrate formation at the hydrate forming conditions, where the KHI is selected from the group consisting of:
a copolymer comprising monomers selected from the group consisting of acryloylmorpholine, vinylimidazole, n-vinyl pyrrolidone and combinations thereof; and
a terpolymer selected from the group consisting of:
acryloylmorpholine, vinylimidazole, and vinylcaprolactam monomers,
vinylimidazole, vinylcaprolactam, and n-vinyl pyrrolidone monomers, and
acryloylmorpholine, vinylimidazole, and n-vinyl pyrrolidone monomers.
12. The method of claim 11 where:
in case the KHI is a copolymer it is a copolymer of acryloylmorpholine and vinylimidazole, and
in case the KHI is a terpolymer it is a terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam.
13. The method of claim 12 where:
in case of the copolymer of acryloylmorpholine and vinylimidazole, the molar ratio of acryloylmorpholine to vinylimidazole ranges from about 1:99 to about 99:1; and
in case of the terpolymer of acryloylmorpholine, vinylimidazole and vinylcaprolactam, the molar ratio of acryloylmorpholine to vinylimidazole to vinylcaprolactam ranges from about 1:1:98 to about 1:98:1 to about 98:1:1.
14. The method of claim 11 where the fluid is present in a wellbore, a pipeline, an umbilical, a pipe, a transfer line, a valve, a slug catcher, and combinations thereof.